Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

B Cell Activation and Differentiation

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CD52 and OXPHOS-potential targets in ibrutinib-treated mantle cell lymphoma.

Cell death discovery·2022

Same author

First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial.

HemaSphere·2022

Same author

MYC multimers shield stalled replication forks from RNA polymerase.

Nature·2022

Same author

Panel Sequencing of Primary Cutaneous B-Cell Lymphoma.

Cancers·2022

Same author

Vitamin D Receptor Expression Is Significantly Decreased in Bone Metastases Compared to Matched Primary Breast Cancer Tumours.

Cancer investigation·2022

Same author

Identification of Disparities in Personalized Cancer Care-A Joint Approach of the German WERA Consortium.

Cancers·2022

Search research articles

Related Experiment Video

Updated: May 8, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification.

German Ott¹, Andreas Rosenwald, Elias Campo

¹Department of Clinical Pathology, Robert-Bosch-Krankenhaus, and Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany;

|September 7, 2013

Summary

This summary is machine-generated.

MYC oncogene activation drives aggressive B-cell lymphomas, often cooperating with other genetic changes. Understanding MYC alterations and protein levels is crucial for diagnosing and managing these challenging cancers.

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

Related Experiment Videos

Last Updated: May 8, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

Area of Science:

Oncology
Hematology
Molecular Biology

Background:

The MYC oncogene is implicated in aggressive B-cell lymphomas, originating from cells not typically expressing MYC.
MYC dysregulation can override normal cellular repressors like BCL6 and BLIMP1.
Aggressive lymphomas often possess additional oncogenic alterations that cooperate with MYC, potentially inhibiting apoptosis.

Purpose of the Study:

To review the role of MYC alterations and protein expression in aggressive B-cell lymphomas.
To integrate recent findings on MYC dysregulation in these neoplasms.
To discuss diagnostic and therapeutic perspectives for MYC-driven lymphomas.

Main Methods:

Utilized fluorescence in situ hybridization (FISH) probes to study MYC gene alterations.
Employed reliable antibodies for assessing MYC protein expression.
Reviewed large patient series to correlate findings with clinical behavior.

Main Results:

MYC gene alterations in large B-cell lymphomas frequently co-occur with BCL2 or BCL6 translocations, indicating aggressive behavior.
MYC protein up-regulation, even without gene alterations, coupled with BCL2 overexpression, predicts a poor prognosis.
Advances in FISH and antibody technology have enhanced the study of MYC in lymphomas.

Conclusions:

MYC dysregulation is a key driver in aggressive B-cell lymphomas, often in conjunction with other genetic events.
Both MYC gene alterations and protein overexpression are significant prognostic indicators.
Further research is needed to address diagnostic and management challenges in MYC-driven aggressive lymphomas.